来源：环球网 7月16日，"科创天府·智汇蓉城"未来产业科技成果对接及生态共创共建专场活动在成都成功举办。本次 活动由成都市委科技委员会办公室、北京邮电大学（以下简称"北邮"）联合主办。活动上，备受瞩目的 北邮未来通信研究院（成都）及北邮兴锦未来通信科技(成都)有限公司正式揭牌。同时，北京邮电大学 集中发布了100余项科技创新成果，一批以北邮教授团队领衔的重大项目及多个校地合作重点项目签约 落地成都，标志着成都未来产业新赛道的创新资源加速聚集与转化。 此次揭牌的北邮未来通信研究院（成都），是今年4月北京邮电大学、中国电信四川公司、成都市科技 局及锦江区四方签署合作协议后筹建的重要成果，标志着"名校、名企、名城"合作新模式进入实质性阶 段。 成都再添高能级创新平台 北邮未来通信研究院（成都）揭牌 活动中，备受瞩目的北邮未来通信研究院(成都)及北邮兴锦未来通信科技(成都)有限公司正式揭牌，据 悉，研究院将在新一代互联网、人工智能等方向开展联合人才培养和核心技术攻关，打造产教融合、概 念验证等创新平台。此外，锦江区未来产业相关企业及四川省量子科技产业协会（筹）同时揭牌。 具体而言：在共建全球领先的通信技术研究院方面 ...

Group 1 - The stock price of Zhixing Technology (01274.HK) surged by 23.31% on July 10, reaching a market capitalization of HKD 4.22 billion after two months of consolidation, driven by multiple positive factors [1] - Zhixing Technology announced on July 10 that it received a designated development notice from a leading domestic brand for five models, including mainstream passenger and commercial vehicles, to provide iDC assisted driving domain controllers and iFC front-view integrated machines [1] - Within 30 days, Zhixing Technology secured a total of 14 model designations, building on the nine commercial vehicle platform designations from early June, showcasing its technical strength and mass production capabilities [1] Group 2 - The new designated projects include ADAS solutions based on the Horizon J6M chip, which will enable advanced driving and parking capabilities, including urban lightweight functions [2] - Zhixing Technology has established a comprehensive service system that supports low, medium, and high-level driving and parking functions, facilitating flexible and cost-effective assisted driving solutions for automakers [1][2] - The company is also focusing on the development of its robotics business, with its subsidiary Aimosing Robotics acquiring a majority stake in Suzhou Xiaogongjian Robotics, enhancing its technological accumulation in key robotic components [2] Group 3 - Aimosing Robotics has completed the full-chain functional verification of its first embodied intelligent product, the "charging robot," which automates the entire charging process [3] - The company is accelerating the development of other core components for the charging robot, aiming to create a highly intelligent and cost-effective product that integrates deeply with Zhixing Technology's high-performance assisted driving product system [3] - Zhixing Technology plans to collaborate with Aimosing in areas such as investment, software and hardware design, supply chain, and manufacturing to expedite the industrialization of Xiaogongjian Robotics [3]

Financial Performance & Guidance - Cerus is raising its full-year 2024 product revenue guidance to $177 - $179 million, anticipating a 12-14% increase compared to full-year 2023 product revenue[13] - The bottom end of the 2024 IFC guidance range has been raised to $9 - $10 million, from the prior $8 - $10 million[13] - In Q3 2024, Non-GAAP Adjusted EBITDA reached $4.4 million[32] Product & Market - The global addressable market for INTERCEPT products is estimated at $1.3 billion, with potential growth to over $1.5 billion in 5-7 years[22] - The U S addressable market is $150 million, with potential growth to over $200 million in 5-7 years[22] - Cerus' preliminary 2023 product revenue was $156 million[22] Strategic Initiatives - Cerus has a new BARDA contract for INTERCEPT RBCs[11] - The company submitted a CE Mark for its LED Illuminator[11] - Cerus is focused on adjusted EBITDA and operating cash flow goals[25]

Financial Performance & Outlook - Cerus achieved positive non-GAAP adjusted EBITDA for Q4 and full year 2024 [9] - The company anticipates product revenue growth of 8% to 11% year-over-year in 2025 [9] - Cerus is committed to sustaining positive adjusted EBITDA for fiscal year 2025 [9] - GAAP net loss attributable to Cerus improved by over 40% in 2024 compared to 2023 [9] - In 2024, Cerus achieved 15% topline growth due to strong team performance and blood center partnerships [10] Market & Product Expansion - Cerus is focused on the continued global expansion of its platelet franchise [9] - The company expects increasing uptake of INTERCEPT Fibrinogen Complex (IFC) in the US [9] - The global addressable market for INTERCEPT products is currently $1.3 billion and is expected to grow to over $1.5 billion in the next 5-7 years [16] - The U S addressable market is $150 million and is expected to grow to over $200 million in the next 5-7 years [16] Technology & Impact - Cumulative kit sales for over 16 million INTERCEPT treated doses of platelets & plasma [5]

Core Insights - The article highlights the remarkable transformation of Pudong over 35 years, from a rural area with a GDP of 6 billion yuan in 1990 to a thriving economic hub with a GDP exceeding 1.7 trillion yuan in 2024, marking a 295-fold increase [1][3] - Pudong has become a key area for China's reform and opening-up, showcasing its role as a modern international metropolis and a leading area for socialist modernization [1][3] Economic Development - The development of Pudong began with a national strategy in 1990, focusing on creating key areas such as the Lujiazui Financial District and Zhangjiang Hi-Tech Park, which laid the foundation for its commercial growth [4][6] - The period from 2000 to 2010 was marked by significant commercial development, with the opening of nearly 20 shopping centers, solidifying the Lujiazui-Zhangyang Road area as a commercial core [6][8] Commercial Landscape - Pudong has seen a surge in high-end consumer population and commercial projects, with over 120 commercial projects currently operational and more than 30 new projects planned in the next three years [2][11] - The Lujiazui financial district is highlighted as a top commercial area, housing over 8,000 financial institutions and numerous shopping centers, making it a prime location for high-end retail [18][20] Future Prospects - Pudong is entering a new phase of high-quality development, with a focus on enhancing domestic demand and expanding its role as a model for national economic growth [10][12] - The area is set to see the development of new urban centers and commercial projects, with significant contributions from state-owned enterprises, which dominate the commercial development landscape [11][14] Brand Presence - Pudong boasts a high concentration of international brands, with 40.36% of shopping center brands being international and 80.48% being national chains, indicating a strong retail environment [15][12] - However, there is a noted challenge of brand homogenization, with a brand duplication rate of 18.56%, suggesting a competitive landscape that may require differentiation strategies [15][12] Commercial Zones - Pudong has established 19 commercial zones, the highest in Shanghai, with the Lujiazui-Zhangyang Road area recognized as the most commercially powerful [16][18] - The emerging Qiantan area is positioned as a new international business center, while the Lingang New Area is expected to see significant commercial growth in the coming years [21][25]

Core Viewpoint - The company has expanded its innovative research and development from monoclonal antibodies to a broader range of drug types, including small molecules, peptides, antibody-drug conjugates (ADCs), bispecific or multispecific antibodies, fusion proteins, and nucleic acid drugs, focusing on next-generation innovative therapies for cancer and autoimmune diseases [1] Group 1: Product Pipeline and Therapeutic Areas - The company's product pipeline covers five major therapeutic areas: malignant tumors, autoimmune diseases, chronic metabolic diseases, neurological diseases, and infectious diseases [1] - Currently, the company has four commercialized drugs: Tuoyi® (特瑞普利单抗), Junmai Kang® (君迈康), Mindewi® (民得维), and Junshida® (君适达) [1] - Nearly 30 drug candidates are in clinical trial stages, with over 20 candidates in preclinical development [1] Group 2: Regulatory Approvals and Market Access - The core product Tuoyi® has received approval for 12 indications in mainland China, with 10 of these indications included in the national medical insurance catalog [1] - The company is accelerating the development and market application of late-stage pipeline products, including anti-BTLA monoclonal antibody tifcemalimab (TAB004/JS004), anti-IL-17A monoclonal antibody (JS005), subcutaneous PD-1 monoclonal antibody formulation (JS001sc), and PD-1/VEGF bispecific antibody (JS207) [1] Group 3: Early-stage Pipeline Exploration - The company continues to explore early-stage pipeline products, including anti-Claudin18.2 ADC (JS107), PI3K-α oral small molecule inhibitor (JS105), CD20/CD3 bispecific antibody (JS203), anti-DKK1 monoclonal antibody (JS015), EGFR/HER3 bispecific antibody conjugate (JS212), and PD-1/IL-2 bifunctional antibody fusion protein (JS213) [1]

恒隆开创内地高端零售先河、太古"十年磨一剑"打造有情怀的商业、新鸿基玩转"地标建筑+TOD"、K11将艺术注入商业、永旺以人性化圈粉，还有"旧改 王者"瑞安、"淘金者"凯德...... 作为商业地产行业的佼佼者，港外资巨头们都各凭本事，在内地市场建立起牢固的竞争壁垒。它们在内地的产品线布局、最新拓展计划，以及明星项目新 动态也成了行业的风向标，备受关注。 赢商网梳理了瑞安、新鸿基、K11、太古、香港置地、恒隆、嘉里、九龙仓、领展、凯德、永旺、SM、英格卡等13个港外资商业地产企业最新商业产品 线、已开和筹开项目的布局情况。 13个企业内地布局40+筹开项目，今年预计将有至少14个新项目入市；内地已成头部港企的"主战场"，上海备受青睐； 外资企业避开高能级市场，重仓非 一线城市；多个新产品线首进内地，产品线更加多元化；多个企业为适应市场变化灵活调整产品定位，有的坚守高端，有的转向次高端，有的押注年轻 化。 01 港资 瑞安房地产 "XINTIANDI新天地"是瑞安旗下的商业品牌，新天地社区是糅合了历史建筑与现代化设施的大型城市社区，遍布全国主要城市中心。其细分为几大产品 线： ■ 城市综合体：瑞安新天地最核心的 ...

Financial Data and Key Metrics Changes - Consolidated net revenue decreased by 7% year over year to $555 million [21] - Consolidated AOI declined by 30% to $104 million, with a margin of 19% [21] - Adjusted EPS was reported at $0.52 [21] - Free cash flow for the quarter was $94 million, on track to achieve approximately $220 million for the full year [20][32] Business Line Data and Key Metrics Changes - Domestic operations revenue decreased by 7% to $486 million, with subscription revenue down by 3% due to a 12% decline in affiliate revenue, partially offset by 8% growth in streaming revenue [21][22] - Advertising revenue in domestic operations decreased by 15% year over year, primarily due to lower linear ratings [26] - International revenue decreased by 7% to $70 million, with subscription revenue down by 12% due to the non-renewal with Movistar in Spain [28] Market Data and Key Metrics Changes - Streaming subscribers remained flat at 10.2 million compared to the prior year, with a slight decline from 10.4 million at the end of 2024 [24][25] - Advertising revenue from streaming is still in the low single digits but provides incremental revenue opportunities [50] Company Strategy and Development Direction - The company focuses on programming, partnerships, and profitability, emphasizing the generation of free cash flow [6][34] - Plans to launch an ad-supported version of Shudder and a new fast channel, Acorn TV Mysteries, to enhance audience engagement and advertising opportunities [10][12] - The company is committed to maintaining a strong balance sheet with no bond maturities until 2029 and over $1 billion in total liquidity [30] Management's Comments on Operating Environment and Future Outlook - Management remains optimistic about the advertising market despite macroeconomic uncertainties, noting strong engagement with advertising partners [26][34] - The company anticipates revenue growth from streaming due to pricing actions and new series debuts [60][62] - Management acknowledges challenges in the linear advertising market but believes in the strength of their programming and advanced advertising capabilities [64] Other Important Information - The company has made refinements to its streaming subscriber definitions to better reflect its distribution strategy [22] - The company is focused on creating high-quality programming while maintaining cost efficiency [72] Q&A Session Summary Question: Can you tell us about the streaming subscribers coming in through bundled video packages? - Management expressed satisfaction with the integration with Charter and the anticipated take rates for embedded streaming services [37] Question: Are you seeing any risk of cannibalization on the a la carte side? - Management believes that expanding distribution will create a healthier video ecosystem and additional revenue opportunities [40] Question: How much of your advertising is coming from streaming? - Streaming advertising contributes incremental revenue, with a focus on integrated partnerships [50] Question: When will you lap the subscription revenue issues from the Spanish drop? - Management indicated that the impact of the non-renewal with Movistar was anticipated and plans are in place to offset revenue changes [51][53] Question: What are your expectations for content spend and amortization this year? - Management stated that cash content spend is expected to be slightly down, but the volume of productions remains flat year over year [69]

Core Viewpoint - AMC Networks reported quarterly earnings of $0.52 per share, missing the Zacks Consensus Estimate of $0.73 per share, and down from $1.16 per share a year ago, indicating a significant earnings surprise of -28.77% [1][2] Financial Performance - The company posted revenues of $555.23 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 3.11%, and down from $596.46 million year-over-year [2] - Over the last four quarters, AMC Networks has surpassed consensus EPS estimates only once and topped consensus revenue estimates two times [2] Stock Performance - AMC Networks shares have declined approximately 37.5% since the beginning of the year, contrasting with the S&P 500's decline of -3.7% [3] - The current Zacks Rank for AMC Networks is 4 (Sell), indicating expectations of underperformance in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.67 on revenues of $589.02 million, and for the current fiscal year, it is $2.31 on revenues of $2.31 billion [7] - The trend for estimate revisions ahead of the earnings release was unfavorable, which may impact future stock movements [6] Industry Context - The Broadcast Radio and Television industry, to which AMC Networks belongs, is currently ranked in the top 38% of over 250 Zacks industries, suggesting a relatively strong industry performance [8]

Gray Media (GTN) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to earnings of $0.79 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 53.06%. A quarter ago, it was expected that this broadcast television company would post earnings of $1.59 per share when it actually produced earnings of $1.59, delivering no surprise.Over the last four quarters, the compan ...